Epithelial ovarian cancer is the most common type of ovarian cancer. It can be easier to treat in the early stages, but as it progresses, it becomes much harder to fully cure. Epithelial ovarian ...

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...

A distinct signaling pathway called TNF- drives the transformation of epithelial cells into aggressive tumor cells. During cancer progression, cells activate their own TNF- program and become invasive ...

Experts have hailed the ‘landmark’ decision from the National Institute for Health and Care Excellence to approve the ...

The NHS is to roll out the first new ovarian cancer treatment in more than 20 years. The drug has been shown to extend survival by almost four months for patients whose cancer has stopped responding ...

Discover the latest targeted therapies and clinical trials for FR-alpha–positive ovarian cancer, including antibody-drug ...

Researchers from The University of Texas MD Anderson Cancer Center have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and ...

Non-Hispanic Black women are less likely to get ovarian cancer than women of other races. But for a number of possible reasons, they are more likely to die from the disease than most other groups.